Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Armin Ghobadi; Michael P. Rettig; Matthew S. Holt; Julie K. Ritchey; Krista Kennerly; Ezhilarasi Chendamarai; Linda Eissenberg; John F. DiPersio

doi:10.1182/blood-2017-10-811620

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Armin Ghobadi, Michael P. Rettig, Matthew S. Holt, Julie K. Ritchey, Krista Kennerly, Ezhilarasi Chendamarai, Linda Eissenberg, John F. DiPersio

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	2594-2596
Number of pages	3
Journal	Blood
Volume	131
Issue number	23
DOIs	https://doi.org/10.1182/blood-2017-10-811620
State	Published - Jun 7 2018

Access to Document

10.1182/blood-2017-10-811620

Cite this

@article{ec817284a23f46ff83b7a50c74a90146,

title = "Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice",

author = "Armin Ghobadi and Rettig, {Michael P.} and Holt, {Matthew S.} and Ritchey, {Julie K.} and Krista Kennerly and Ezhilarasi Chendamarai and Linda Eissenberg and DiPersio, {John F.}",

note = "Funding Information: J.F.D. is supported by grants from the National Institutes of Health, National Cancer Institute (U54 CA199092 [principal investigator: S. Achelifu], R01 CA152329-A1 [principal investigator: J.F.D.], and R35 CA210084-01A [principal investigator: J.F.D.]). A.G. is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2 TR002346 (principle investigator: Victoria J. Fraser). M.P.R. is supported by the National Institutes of Health, National Cancer Institute (R50 CA211466). Takeda Pharmaceuticals provided ixazomib.",

year = "2018",

month = jun,

day = "7",

doi = "10.1182/blood-2017-10-811620",

language = "English",

volume = "131",

pages = "2594--2596",

journal = "Blood",

issn = "0006-4971",

number = "23",

}

TY - JOUR

T1 - Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

AU - Ghobadi, Armin

AU - Rettig, Michael P.

AU - Holt, Matthew S.

AU - Ritchey, Julie K.

AU - Kennerly, Krista

AU - Chendamarai, Ezhilarasi

AU - Eissenberg, Linda

AU - DiPersio, John F.

N1 - Funding Information: J.F.D. is supported by grants from the National Institutes of Health, National Cancer Institute (U54 CA199092 [principal investigator: S. Achelifu], R01 CA152329-A1 [principal investigator: J.F.D.], and R35 CA210084-01A [principal investigator: J.F.D.]). A.G. is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2 TR002346 (principle investigator: Victoria J. Fraser). M.P.R. is supported by the National Institutes of Health, National Cancer Institute (R50 CA211466). Takeda Pharmaceuticals provided ixazomib.

PY - 2018/6/7

Y1 - 2018/6/7

UR - http://www.scopus.com/inward/record.url?scp=85048397010&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-10-811620

DO - 10.1182/blood-2017-10-811620

M3 - Letter

C2 - 29695518

AN - SCOPUS:85048397010

SN - 0006-4971

VL - 131

SP - 2594

EP - 2596

JO - Blood

JF - Blood

IS - 23

ER -

Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice

Access to Document

Other files and links

Cite this